The JAK/STAT3 axis: A comprehensive drug target for solid malignancies

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The tumor microenvironment involves complex intercellular communication essential for tumor growth and metastasis.
• Signal transducer and activator of transcription 3 (STAT3) signaling is critical for tumor cell proliferation, survival, and modulation of the tumor microenvironment.
• Aberrant STAT3 activation, often induced by IL-6 and IL-10 family cytokines, is a hallmark of many malignancies.

Purpose of the Study:

• To provide an update on the role of STAT3 in immune suppression within the tumor microenvironment.
• To describe current therapeutic strategies targeting the Janus kinase (JAK)/STAT3 signaling axis for cancer treatment.

Main Methods:

• Review of existing literature on STAT3 signaling in cancer and immune suppression.
• Analysis of therapeutic strategies targeting the JAK/STAT3 pathway.

Main Results:

• STAT3 signaling influences both tumor cell-intrinsic properties and the functions of surrounding immune and stromal cells.
• Tumor-extrinsic STAT3 signaling contributes to immune suppression by impairing anti-tumor immune responses.
• The JAK/STAT3 pathway is implicated in mediating tumorigenic effects across various cell types.

Conclusions:

• STAT3 plays a dual role in cancer, promoting tumor growth and mediating immune suppression.
• The molecular components of the JAK/STAT3 pathway represent viable therapeutic targets for cancer treatment.
• Targeting the JAK/STAT3 axis is a promising strategy for overcoming immune evasion and treating malignancies.